Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 111, Issue 9, 2011, Pages 16-22

  Gavrilova, S I ^a   Kalyn, YA B ^a   Kolykhalov, I V ^a   Roshchina, I F ^a   Selezneva, N D ^a  

^a NONE

Author keywords

Acetyl L carnitine (carnicetine); Alzheimer's disease; Initial stage of disease; Mild cognitive impairment; Vascular dementia

Indexed keywords

CARNICETINE; LEVACECARNINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST;

EID: 80054756696     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Russian Source
2. Amenta F., Ferrante F., Lucreziotti R. et al. Reduced lipofuscin accumulation in senescent rat brain by long-term acetyl-L-carnitine treatment. Arch Gerontol Geriatr 1989; 9: 147-153.
3. Angelucci L., Ramacci M.T., Taglialatela G. et al. Nerve growth factor binding in aged rat central nervous system: effect of acetyl-L-carnitine. J Neurosci Res 1988; 20: 491-496.
4. Bagetta V., Barone I., Ghiglieri V. Acetyl-l-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. Neuropharmacology 2008; 55: 2: 223-229.
5. Bianchetti A., Rozzini R., Trabucchi M. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Curr Med Res Opin 2003; 19: 4: 350-353.
6. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983; 63: 1420-1480.
7. Brooks J.O. 3rd, Yesavage J.A., Carta A., Bravi D. Acetyl-L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. Int Psychoger 1998; 10: 193-203.
8. Calvani M., Arrigoni-Martelli E. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Int J Tissue React 1999; 21: 1-6.
9. Castorina M., Ambrosini A.M., Pacific L. et al. Age-dependent loss of NM-DA receptors in hippocampus, striatum, and frontal cortex of the rat: prevention by acetyl-L-carnitine. Neurochem Res 1994; 19: 795-798.
10. Epis R., Marcello E., Gardoni F. et al. Modulatory effect of acetyl-l-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol 2008; 597: Issues 1-3: 51-56.
11. Hagen T.M., Moreau R., Suh J.H., Visioli F. Mitochondrial decay in the aging rat heart. Ann NY Acad Sci 2002; 959: 491-507.
12. Harsing L.G. Jr., Sershen H., Toth E. et al. Acetyl-L-carnitine releases dopamine in rat corpus striatum: an in vivo microdialysis study. Eur J Pharmacol 1992; 218: 117-121.
13. Imperato A., Ramacci M.T., Angelucci L. Acetyl-Lcarnitine enhances acetyl-choline release in the striatum and hippocampus of awake freely moving rats. Neurosci Lett 1989; 107: 251-255.
14. Soczynska J.K., Kennedy S.H., Chow C.S.M. Expert Opin Investig Drugs 2008; 17: 6: 827-843.
15. Montgomery S.A., Thal L.J., Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003; 18: 61-71.
16. Pascale A., Milano S., Corsico N. et al. Protein kinase C activation and anti-amnesic effect of acetyl-L-carnitine: in vitro and in vivo studies. Eur J Pharmacol 1994; 65: 1-7.
17. Pettegrew J.W., Klunk W.E., Panchalingam K. et al. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. Neurobiol Aging 1995; 16: 1-4.
18. Pettegrew J.W., Levine J., McClure R.J. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Molecular Psychiatry 2000; 5: 616-632.
19. Piovesan P., Pacifici L., Taglialatela G. et al. Acetyl-L-carnitine treatment increases choline acetyltransferase activity and NGF levels in the CNS of adult rats following total fimbria-fornix transection. Brain Res 1994; 633: 77-82.
20. Sano M., Bell K., Cote L. et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's Disease. Arch Neurol 1992; 49: 1137-1141.
21. Taglialatela G., Caprioli A., Giuliani A. et al. Spatial memory and NGF levels in aged rats: natural variability and effects of acetyl-L-carnitine treatment. Exp Gerontol 1996; 31: 577-587.
22. Tempesta E., Janiri L., Pirrongelli C. Stereospecific effects of acetylcarnitine on the spontaneous activity of brainstem neurones and their responses to acetylcholine and serotonin. Neuropharmacology 1985; 24: 43-50.
23. Thal L.J., Carta A., Clarke W.R. et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's Disease. Neurology 1996; 47: 705-711.
24. Toth E., Harsing L.G., Sershen H. et al. Effect of acetyl-L-carnitine on extracellular amino acid levels in vivo in rat brain regions. Neurochem Res 1993; 18: 573-578.
25. White H.L., Scates P.W. Acetyl-L-carnitine as a precursor of acetylcholine. Neurochem Res 1990; 15: 597-601.